A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease-Reference-Cited by-同舟云学术

A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease

Published:2017-04-03 Issue:5 Volume:32 Page:783-789
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Olanow C. Warren¹²,Kieburtz Karl¹³,Leinonen Mika¹⁴,Elmer Lawrence⁵,Giladi Nir⁶,Hauser Robert A.⁷,Klepiskaya Olga S.⁸,Kreitzman David L.⁹,Lew Mark F.¹⁰,Russell David S.¹¹,Kadosh Shaul¹²,Litman Pninit¹³,Friedman Hadas¹³,Linvah Nurit¹³,the PB Study Group for¹

Affiliation:

1. Clintrex LLC, Rye; New York USA

2. Mount Sinai School of Medicine; New York New York USA

3. University of Rochester School of Medicine; Rochester New York USA

4. 4Pharma AB; Stockholm Sweden

5. Gardner-McMaster Parkinson Center; University of Toledo; Toledo Ohio USA

6. Parkinson's Disease and Movement Disorders Center; National Parkinson Foundation (NPF) Center of Excellence, Neurological Institute, Tel-Aviv Medical Center, Sackler School of Medicine, Sagol School of Neuroscience, Tel Aviv University; Tel Aviv Israel

7. University of South Florida Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence; Tampa Florida USA

8. University of Colorado School of Medicine; Denver Colorado USA

9. Parkinson's Disease and Movement Disorder Center of Long Island; Commack New York USA

10. University of Southern California (USC)/Keck School of Medicine; Los Angeles California USA

11. Institute for Neurodegenerative Disorders; New Haven Connecticut USA

12. StatExcellence Ltd; Nesher Israel

13. Pharma Two B Ltd; Rehovot Israel

Funder

Pharma Two B Ltd

Publisher

Wiley

Subject